FOLH1 and prostate cancer: The higher uptake and internalization of compound 1 in LNCaP cells compared to non-malignant HEK-293 cells across all time points (Table S2) underscores its strong PSMA-targeting specificity and preferential accumulation in prostate cancer cells.